2026 · 2nd Quarter (Apr 1 - June 30)

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Filed by THE MCMANUS GROUP.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 20, 2026
Income: $60,000.00
Expenses: Not reported
Registrant: THE MCMANUS GROUP
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Filing UUID: d2530ae0-1069-40c3-bf80-e9979b5a7e5b
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model

Literal federal measure citations: S. 832, H.R. 1492, H.R. 4299

HCR · Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.

TAX · Taxation/Internal Revenue Code

Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).

Literal federal measure citations: H.R. 9504

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.